Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) Director Robert Kraft sold 3,858 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $617.81, for a total value of $2,383,510.98. Following the completion of the transaction, the director owned 955 shares of the company's stock, valued at $590,008.55. The trade was a 80.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Medpace Stock Down 1.8%
NASDAQ:MEDP opened at $600.65 on Friday. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The company has a market capitalization of $16.76 billion, a P/E ratio of 35.21, a P/E/G ratio of 2.73 and a beta of 1.15. The stock's fifty day moving average is $565.33 and its two-hundred day moving average is $494.55.
Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company's quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.
Institutional Trading of Medpace
Several hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System lifted its holdings in Medpace by 22.1% during the 1st quarter. California State Teachers Retirement System now owns 26,042 shares of the company's stock worth $12,505,000 after buying an additional 4,719 shares in the last quarter. American Capital Management Inc. purchased a new position in Medpace in the 2nd quarter valued at approximately $111,329,000. Focus Partners Advisor Solutions LLC acquired a new position in shares of Medpace in the second quarter worth $1,685,000. BlackRock Inc. acquired a new position in shares of Medpace in the second quarter worth $1,323,047,000. Finally, Cerity Partners LLC increased its position in shares of Medpace by 41.0% during the fourth quarter. Cerity Partners LLC now owns 80,973 shares of the company's stock worth $45,478,000 after acquiring an additional 23,530 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts have weighed in on the stock. Weiss Ratings raised shares of Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 12th. Barclays set a $600.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. TD Cowen upped their price target on Medpace from $419.00 to $492.00 and gave the stock a "hold" rating in a research note on Friday, July 24th. Finally, Jefferies Financial Group lowered Medpace from a "buy" rating to a "hold" rating and raised their price target for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, Medpace presently has an average rating of "Hold" and a consensus price target of $584.18.
Read Our Latest Report on Medpace
Medpace Company Profile
(
Get Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
